Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/28/24 | $100,000,000 | Series A |
ARCH Venture Partners PureTech Health Sofinnova Investments Third Rock Ventures | undisclosed |
| 11/07/24 | $225,000,000 | Series B |
ARCH Venture Partners CPP Investments Foresite Capital General Atlantic Goldman Sachs Invus Capital PureTech Health Sofinnova Ventures T. Rowe Price Associates Third Rock Ventures | undisclosed |
